RomânăFără categorie
A single blood test for 50 types of cancer: What are MCED tests (Galleri core test) and how can they change cancer treatment
Imagine going to your family doctor for a routine check-up and, through a simple blood test — as common as a complete blood count — you can find out if your body is producing early signs of cancer somewhere. Not for just one type of cancer, but for dozens. This is no longer science fiction. It’s called the MCED test ( Multi-Cancer Early Detection ) and the most advanced representative of this category, the Galleri test , was recently validated on nearly 36,000 participants in the PATHFINDER 2 clinical trial .
If you are a patient, a caregiver, or simply want to understand what’s new about this technology and what it means for cancer treatment , this guide is for you.
1. 🔬 What is an MCED test and how does it work?
MCED ( Multi-Cancer Early Detection ) tests represent a new class of medical tests that use a single blood sample to simultaneously look for molecular signs of dozens of types of cancer , many of them before the patient has any symptoms.
How do they do this? By analyzing circulating tumor DNA (cfDNA — cell-free DNA) :
- When cancer cells divide or die, they release small fragments of genetic material (DNA) into the bloodstream.
- An MCED test collects a blood sample and uses advanced bioinformatics algorithms to detect the methylation patterns of this DNA.
- DNA methylation is a kind of molecular “fingerprint” — each type of cell in the body (including cancer cells in different organs) has a unique methylation pattern.
- Based on this pattern, the test not only detects the presence of a cancerous signal , but also predicts the tissue origin — that is, it tells the doctor: “the signal seems to be coming from the pancreas” or “from the lungs.”
In short: One blood test, one laboratory analysis, dozens of types of cancer investigated simultaneously.
2. 📊 Galleri test and PATHFINDER 2 study: What do the data say?
The Galleri test , developed by the American company GRAIL , is currently the most studied and validated MCED test in the world. The largest clinical validation study, PATHFINDER 2 , included 35,878 adult participants — a cohort of remarkable size in the field of preventive oncology.
What did PATHFINDER 2 demonstrate?
- Detection of a cancer signal: In one percent of participants, the test identified a positive signal for cancer. Subsequently, following further investigations, a significant proportion of them received a confirmed diagnosis of cancer , including cancers for which there are currently no standard screening programs (pancreatic, ovarian, liver cancer, etc.).
- Accuracy of tissue origin prediction: When the test detected a positive signal and indicated an organ of origin, this prediction proved correct in approximately 88% of cases — a remarkable result, as it quickly guides subsequent imaging investigations (CT, MRI, PET-CT), saving valuable time.
- Low false-positive rate: One of the biggest fears in screening is the anxiety generated by false alarms. The Galleri test has demonstrated high specificity (over 99%) , meaning that the probability of receiving a false positive result is extremely low.
- Early-stage cancers: A significant proportion of the cancers detected in the study were in stages I and II — precisely the stages where treatment has the greatest chance of success and cure.
💡 Note: PATHFINDER 2 is not a small or preliminary study. With nearly 36,000 participants, it provides a solid statistical basis for assessing the test’s actual performance in the general population.
3. ✅ What can (and cannot) the Galleri test detect?
It is essential to understand both the power and limitations of this test, so as not to create unrealistic expectations.
What the Galleri test can do:
- Detects signals for over 50 types of cancer from a single blood sample
- Identify cancers for which there is no standard screening , such as:
- Pancreatic cancer
- Ovarian cancer
- Liver cancer
- Lung cancer (outside chest CT programs)
- Hematological cancers (lymphomas, multiple myeloma)
- Predicts the organ of origin with high accuracy, guiding further investigations
- Detect cancers in their early stages , when treatment is more effective
What the Galleri test does NOT do (important limitations to know):
- ❌ It does not replace standard screenings already validated: mammography, colonoscopy, Pap smear, PSA remain the first-line recommendations for the cancers it covers
- ❌ A negative result does not guarantee the absence of cancer — sensitivity varies by cancer type and stage; very early or small cancers may not release enough circulating DNA to be detected
- ❌ It is not a diagnostic test — a positive result requires imaging and biopsy for confirmation.
- ❌ Sensitivity varies depending on the type of cancer: it is higher for cancers that release large amounts of cfDNA (e.g. hematological cancers) and lower for others (e.g. brain cancers)
4. 💊 How do MCED tests change the therapeutic approach? Major implications in treatment
This is perhaps the most important question. Why does it matter that a cancer is discovered early? The answer is one, but with huge consequences: the stage at diagnosis dictates almost everything in oncology.
4.1. Simpler and less aggressive treatment
- Breast cancer discovered at stage I can often be treated with conservative surgery (lumpectomy) + localized radiotherapy , without aggressive chemotherapy.
- The same cancer, discovered at stage IV (metastatic), requires long-term systemic chemotherapy , with significant side effects and greatly reduced chances of cure.
- The earlier the stage, the better tolerated and shorter the therapeutic regimen .
4.2. Dramatic increase in survival rate
International oncology statistics (SEER Database, NCI) show radical differences in 5-year survival depending on the stage at diagnosis:
| Type of cancer | 5-year survival — Stage I | 5-year survival — Stage IV |
| Breast cancer | ~99% | ~28% |
| Colon cancer | ~90% | ~13% |
| Lung cancer | ~61% | ~7% |
| Pancreatic cancer | ~44% | ~3% |
The data speaks for itself. Early detection is not a marginal advantage—it is the difference between life and death in many situations.
4.3. Revolutionizing the treatment of “silent” cancers
Pancreatic, ovarian, and liver cancers are called “silent killers” because they do not produce symptoms in the early stages. When they become symptomatic, they are already, in the vast majority of cases, at stage III or IV . There are no population screening programs for these types of cancer.
The MCED test could radically change this picture: detecting a pancreatic signal in stage I opens the window for curative surgical resection — the only real chance of cure in pancreatic cancer — instead of palliative chemotherapy.
4.4. Guiding investigations and avoiding the “diagnostic odyssey”
By indicating the organ of origin with an accuracy of ~88%, the MCED test avoids the situation in which the doctor has to “blindly” “search” for cancer throughout the body, exposing the patient to multiple investigations, high costs and, above all, loss of time. The oncologist can directly direct imaging investigations and biopsy to the indicated organ.
4.5. Implications for personalized treatments and precision medicine
Early detection through MCED paves the way for:
- Early molecular profiling: if the tumor is discovered early, biopsy and genomic tests (NGS — Next Generation Sequencing) can be performed immediately, identifying targetable mutations (BRCA, KRAS, EGFR, etc.) and selecting the most appropriate targeted therapy before the disease progresses
- Early immunotherapy: tumors discovered in early stages are more receptive to immunotherapy, as the patient’s immune system is not yet “exhausted” by advanced disease
- Reducing treatment costs: treating a stage I cancer costs 3-5 times less than managing a metastatic cancer, involving shorter hospitalizations and fewer lines of treatment
5. 🙋 Who should consider an MCED test?
MCED testing is not currently recommended for the entire population , and international guidelines (NCCN, USPSTF) have not yet issued formal recommendations for universal screening. However, there are high-risk categories for whom discussing these tests with your doctor makes sense:
- ✔️ People over 50 years of age with no other identified risk factors
- ✔️ People with a family history of cancer (especially cancers for which there is no standard screening: pancreatic, ovarian, liver)
- ✔️ Current or former smokers (increased risk for multiple cancers, not just lung)
- ✔️ People who have undergone chemotherapy or radiotherapy in the past (risk of secondary cancers)
- ✔️ Carriers of genetic mutations (BRCA1/2, Lynch syndrome, etc.)
- ✔️ People with obesity, type 2 diabetes or liver cirrhosis (validated oncological risk factors)
⚠️ Important: The decision to perform an MCED test should be made in conjunction with a medical specialist , who can contextualize the results in the patient’s complete clinical picture.
🔑 Summary: What to remember about MCED tests
| appearance | Conclusion |
| What is it? | Blood test detects signals for 50+ types of cancer |
| Validation study | PATHFINDER 2 — 35,878 participants |
| Specificity | >99% (very rare false alarms) |
| Accuracy of origin prediction | ~88% |
| Does it replace standard screenings? | No — complete them |
| Is it diagnostic? | No — requires confirmation by imaging and biopsy |
| The biggest benefit | Detection of cancers without standard screening (pancreas, ovary, liver) |
| Therapeutic implication | Simpler, more effective, better tolerated treatment, much higher survival rates |
📊 Synthesis Diagrams — MCED (Galleri) Tests on Patient Understanding
🔷 TABLE 1 — What is the MCED / Galleri test? (Overview)
| Question | Simple answer |
| 📌 What is it? | A blood test that looks for signs of cancer in multiple organs simultaneously |
| 🧬 How does it work? | Detects tumor DNA fragments released by cancer cells into the blood |
| 🔢 How many types of cancer can it detect? | Over 50 types from a single blood sample |
| 👥 How many people were tested? | 35,878 participants in the PATHFINDER 2 study |
| ⏱️ How long does the harvest take ? | Just like a regular blood test — a few minutes |
| 💡 What does it do in addition to normal analyses? | Detects cancers for which there is no standard screening (pancreas, ovary, liver) |
| ✅ Is it a diagnostic test? | NO — if positive, further investigations are necessary (CT, MRI, biopsy) |
| ❌ Does it replace mammography, colonoscopy, PSA? | NO — complements them, does not replace them |
🔷 TABLE 2 — Galleri Test Performance (PATHFINDER 2 Study Results)
| What does it measure? | Result obtained | What does it mean to you? |
| 🎯 Specificity (false alarms) | Over 99% | The probability of receiving a false positive result is extremely low. |
| 🗺 ️ Accuracy of identification of the organ of origin | ~88% | If the test is positive, in 9 out of 10 cases it correctly indicates the affected organ |
| 🔬 Cancers detected in early stages (I and II) | Significant proportion | Precisely the stages where treatment has the greatest chance of success |
| 🚨 Cancers without standard screening detected | Yes (pancreas, ovary, liver) | Cancers that would otherwise only be discovered at an advanced stage |
| 📊 Number of study participants | 35,878 | One of the largest studies of its kind in the world |
🔷 TABLE 3 — What the MCED test can and cannot do
| ✅ WHAT IT CAN DO | ❌ WHAT IT CANNOT DO |
| Detects signals for 50+ types of cancer | Replace mammography, colonoscopy or other standard screenings |
| Identify cancers without a screening program (pancreas, ovary, liver) | Guaranteed not to have cancer if the result is negative |
| Predicts organ of origin with ~88% accuracy | Make a self-diagnosis |
| Detects cancers in early stages (I and II) | Worked perfectly for all types of cancer (variable sensitivity) |
| Quickly guide subsequent imaging investigations | Detects very small cancers that don’t release enough DNA into the blood |
| Reduces time to diagnosis | Eliminates the need for biopsy for confirmation |
🔷 TABLE 4 — Why does stage at diagnosis matter? (5-year survival)
💬 This is the main reason why MCED tests are so important — the earlier cancer is discovered, the better the chances of cure.
| Type of cancer | 😊 Stage I (early) | 😔 Stage IV (advanced) | 💥 The difference |
| 🎀 Breast cancer | ~99% | ~28% | +71 percentage points |
| 🟤 Colon cancer | ~90% | ~13% | +77 percentage points |
| 🫁 Lung cancer | ~61% | ~7% | +54 percentage points |
| 🟡 Pancreatic cancer | ~44% | ~3% | +41 percentage points |
⚠️ Sources: NCI SEER Database, international cancer survival statistics
🔷 TABLE 5 — How does the MCED test change treatment? (Therapeutic implications)
| If cancer is discovered EARLY (stage I-II) | If the cancer is discovered LATE (stage III-IV) |
| ✅ Conservative surgery (less invasive ) | ❌ Extensive or impossible surgical interventions |
| ✅ Localized radiotherapy , on a small area | ❌ Aggressive systemic chemotherapy , throughout the body |
| ✅ Shorter treatment duration | ❌ Long-term treatment, for years |
| ✅ Fewer and milder side effects | ❌ Severe side effects ( nausea , extreme fatigue , hair loss ) |
| ✅ Treatment costs 3-5 × lower | ❌ Very high costs ( multiple hospitalizations, successive lines of treatment ) |
| ✅ Much higher survival rates | ❌ Significantly reduced survival rates |
| ✅ Better quality of life during treatment | ❌ Quality of life severely affected |
🔷 TABLE 6 — Who should consider an MCED test?
| Risk category | Why is the MCED test relevant? | Priority level |
| 👴👵 People over 50 years old | The incidence of cancer increases significantly after this age. | 🔴 High |
| 👨 👩 👧 Family history of cancer | Increased genetic risk, especially for cancers without standard screening | 🔴 High |
| 🚬 Current or former smokers | Increased risk for multiple cancers (not just lung) | 🔴 High |
| 🧬 Carriers of genetic mutations (BRCA, Lynch) | Substantial risk for multiple types of cancer simultaneously | 🔴 High |
| ⚕️ Patients with chemotherapy / radiotherapy in the past | Risk of secondary cancers induced by previous treatments | 🟠 Medium-high |
| ⚖️ People with obesity or type 2 diabetes | Scientifically validated oncological risk factors | 🟠 Medium-high |
| 🫀 People with liver cirrhosis | Increased risk of liver cancer | 🟠 Medium-high |
| 🙋 People without special risk factors | General preventive screening can be discussed with your doctor. | 🟡 To discuss with the doctor |
🔷 TABLE 7 — Steps to follow after a POSITIVE MCED result
| Step | What are you doing? | Why is it important? |
| 1️ ⃣ | Don’t panic — a positive result requires confirmation | The specificity of the test is >99%, but confirmation is mandatory |
| 2️⃣ | or family doctor urgently | He will coordinate further investigations. |
| 3️ ⃣ | Performs imaging investigations indicated by the test (CT / MRI / PET-CT) | MCED test indicates organ of origin — investigations confirm exact location |
| 4️ ⃣ | Performs biopsy from the area identified by imaging | The only method to definitively confirm the diagnosis |
| 5️ ⃣ | Request molecular profiling (IHC/NGS) of the biopsy | Identify mutations and guide personalized treatment choices |
| 6️ ⃣ | Upload the file to Oncoexpertai.com | You receive an AI analysis correlated with NCCN and ESMO guidelines and a second oncological opinion |
| 7️ ⃣ | Present yourself to the Oncology Commission (Tumor Board) with the complete file | The final therapeutic decision is made by a multidisciplinary team. |
🔷 TABLE 8 — MCED Test vs. Traditional Screenings (Simple Comparison)
| Criterion | MCED Test (Galleri) | Traditional screenings (mammography, colonoscopy, etc.) |
| 📌 Number of cancers investigated | 50+ types simultaneously | 1 type per investigation |
| 🩸 Method | Simple blood test | Imaging, endoscopy, specific procedures |
| 😣 Discomfort | Minimum (syringe needle) | Variable (some procedures require preparation or sedation) |
| 🔬 Cancers without standard screening | ✅ Yes (pancreas, ovary, liver) | ❌ No (only covers the cancers for which they are designed) |
| 📋 Official international recommendation | In the process of validation/approval (FDA, ESMO) | ✅ Official standardized recommendation |
| 🏥 Does it replace other screenings? | NO — complete them | They remain recommended as first line |
| 💊 Action if positive | Mandatory additional investigations | Biopsy / immediate treatment (depending on the result) |
. 🤖 How does Oncoexpertai help in interpreting a positive MCED result?
A positive MCED test result — that is, the detection of a signal of cancer — can be one of the most stressful moments in a patient’s life. Questions come in waves: What organ is affected? What investigations do I do next? Which doctor should I see? How urgent is it?
This is exactly where the Oncoexpertai platform comes in .
Our advanced Artificial Intelligence algorithms can:
- Correlate the MCED signal with your complete medical profile (age, gender, family history, previous tests, risk factors)
- Identify priority imaging investigations recommended by NCCN and ESMO international guidelines for the organ of origin indicated by the test
- Quickly analyze and interpret biopsy and subsequent genomic test results
- Compares the proposed therapeutic regimen with international protocols updated in real time, providing an informed digital oncology second opinion
Technology does not replace the oncologist — it provides them with more information, faster and better structured , so that the therapeutic decision can be made with complete certainty.
📩 Did you receive a positive MCED result or do you want to better understand your screening options?
Upload your medical file to Oncoexpertai.com and receive a personalized analysis performed with the help of artificial intelligence, correlated with the latest international oncology guidelines.
Disclaimer: The information in this article is for informational and educational purposes only and does not constitute medical advice, diagnosis or therapeutic recommendation. The Galleri test and MCED tests are clinical tools that should be used and interpreted exclusively by specialist doctors. Before making any medical decision, always consult an oncologist or your family doctor. Oncoexpertai does not provide medical diagnosis, but digital support in understanding medical documents and accessing the second oncological opinion.
- Main keywords: MCED test, Galleri test, early cancer detection, PATHFINDER 2, circulating tumor DNA, multi-cancer screening
Article published on oncoexpertai.com | Updated: July 2026 Sources: PATHFINDER 2 Study (GRAIL/Illumina), NCCN Guidelines, ESMO Clinical Practice Guidelines, NCI SEER Database
Dr. Onisim Florin Senior Medical Oncologist Founder of OncoExpertAI